Retrospective validation of genomic biomarkers-- what are the questions, challenges and strategies for developing useful relationships to clinical outcomes-- workshop summary.
Wang
S-J
SJ
Office of Biostatistics, Office of Pharmacoepidemiology and Statistical Science, Center for Drug Evaluation and Research, US FDA, Silver Spring, MD 20993, USA. wangs@cder.fda.gov
Cohen
N
N
Katz
D A
DA
Ruano
G
G
Shaw
P M
PM
Spear
B
B
D002986:Clinical Trials as Topic; D015195:Drug Design; D004345:Drug Industry; D023381:Endpoint Determination; D005819:Genetic Markers; D023281:Genomics; D010597:Pharmacogenetics / Q000379:methods*; D012189:Retrospective Studies; D014481:United States; D014486:United States Food and Drug Administration
D005819:Genetic Markers